Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Ahlen – page 46

864 clinical trials in Ahlen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ahlen at a glance
864
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

864 trials in Ahlen

Open in trial search

Acute kidney injury

Not recruiting

Study of GDC-8264 compared to placebo for preventing kidney injury in patients at risk of acute kidney injury after heart surgery

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7288817
  • Sponsor:Genentech Inc.

Hereditary angioedema

Not recruiting

Study of Deucrictibant Extended-Release Tablets for Prevention of Hereditary Angioedema Attacks in Adults and Adolescents

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Study on the Effectiveness and Safety of Datopotamab Deruxtecan Compared to Chemotherapy in Adults with Advanced Triple-negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study on the Effectiveness and Safety of Benralizumab with Budesonide and Formoterol in Patients with Eosinophilic Asthma Uncontrolled by Standard Treatment

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Obesity+1

Not recruiting

Study on the Effectiveness of Orforglipron for Patients with Obstructive Sleep Apnea and Obesity or Overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Hidradenitis

Not recruiting

Study on the Effectiveness of IC0624 for Patients with Mild to Moderate Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Sodium bituminosulfonate dry substance
  • Sponsor:Ichthyol-Gesellschaft Cordes Hermanni & Co. GmbH & Co. KG

Migraine

Not recruiting

Study on Atogepant for Preventing Menstrual Migraine in Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Atogepant
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Quizartinib with Chemotherapy for Adults with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Daiichi Sankyo Inc.

Urticaria chronic

Not recruiting

Study on Long-Term Safety of Briquilimab for Patients with Chronic Urticaria

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Briquilimab
  • Sponsor:Jasper Therapeutics Inc.

Study of Amlenetug for Patients with Multiple System Atrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amlenetug
  • Sponsor:H. Lundbeck A/S

Study of PF-06821497 and Enzalutamide for Men with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Ahlen

What the registry says about research in the country

01 Neoplasms (Cancer) Research

In Ahlen, researchers are conducting two recruiting neoadjuvant studies that target HER2+ early breast cancer and triple-negative early breast cancer. The trials compare novel antibody‑drug conjugates with standard chemotherapy regimens, aiming to improve safety profiles and increase pathological complete response rates.

  • Safety profiling of a trastuzumab‑deruxtecan based regimen
  • Efficacy comparison using 3‑year distant disease‑free survival
  • Assessment of sacituzumab govitecan with or without pembrolizumab
  • Evaluation of pathological complete response as a co‑primary endpoint

The single study center in Ahlen enables close coordination between the investigator team and participating patients, fostering rapid enrollment and data collection for these cutting‑edge breast cancer studies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.